comparemela.com
Home
Live Updates
Stoke Therapeutics Announces Landmark New Data That Support
Stoke Therapeutics Announces Landmark New Data That Support
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
– Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines; Median reductions...
Related Keywords
United Kingdom ,
United States ,
Ukraine ,
Bedford ,
Massachusetts ,
Cambridge ,
Cambridgeshire ,
Edwardm Kaye ,
Joseph Sullivan ,
Drug Administration ,
Company Annual Report On Form ,
Nasdaq ,
University Of California San Francisco ,
Stoke Therapeutics Inc ,
Augmentation Of Nuclear Gene Output ,
Pediatric Epilepsy Center ,
Exchange Commission ,
Stoke Therapeutics ,
Chief Executive Officer ,
California San Francisco ,
Study Results ,
Sustained Reductions ,
Convulsive Seizure ,
Convulsive Seizure Frequency ,
After Last Dose ,
Label Extension Studies ,
Vineland Adaptive Behavior Scale ,
Suspected Unexpected Serious Adverse Reactions ,
Conference Call ,
United Kingdom Studies ,
American Epilepsy Society ,
Targeted Augmentation ,
Nuclear Gene Output ,
Private Securities Litigation Reform Act ,
Middle East ,
Annual Report ,
Markets ,